ArticleThe American journal of bioethics : AJOB2024
First-in-Human Whole-Eye Transplantation: Ensuring an Ethical Approach to Surgical Innovation.
Article in The American journal of bioethics : AJOB, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Who should be included in first-in-human trials? A systematic review of reasons.Journal of translational medicine · 2025Pooled it
- Reassessing Ethical Considerations in Pediatric Facial Transplantation: Where Are We Now?Plastic and reconstructive surgery. Global open · 2026Article
- Is There an Increasing Interest in Vascular Composite Allotransplantation? A Search Trends Analysis.Plastic and reconstructive surgery. Global open · 2026Article
- Epidemiological and Surgical Insights Into Concomitant Ocular and Craniofacial Trauma and the Implications for Combined Face and Whole-eye Transplantation.Plastic and reconstructive surgery. Global open · 2026Article
- Mortality and graft loss in face transplantation: lessons from two decades of experience.Clinical transplantation and research · 2026Review
- Zero Warm Ischemia Time in Whole-Eye Transplantation through Retrograde Extracorporeal Perfusion.Ophthalmology science · 2026Article
- Allogeneic whole-eye transplantation: advancements, challenges, and future directions in vision restoration.Frontiers in medicine · 2025Review
- Whole-eye transplantation: Current challenges and future perspectives.World journal of transplantation · 2024Review
- Whether Whole Eye Transplant is a Benefit or Harm Depends on More Than the Observer.The American journal of bioethics : AJOB · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As innovations in the field of vascular composite allotransplantation (VCA) progress, whole-eye transplantation (WET) is poised to transition from non-human mammalian models to living human recipients. Present treatment options for vision loss are generally considered suboptimal, and attendant concerns ranging from aesthetics and prosthesis maintenance to social stigma may be mitigated by WET. Potential benefits to WET recipients may also include partial vision restoration, psychosocial benefits related to identity and social integration, improvements in physical comfort and function, and reduced surgical risk associated with a biologic eye compared to a prosthesis. Perioperative and postoperative risks of WET are expected to be comparable to those of facial transplantation (FT), and may be similarly mitigated by immunosuppressive protocols, adequate psychosocial support, and a thorough selection process for both the recipient and donor. To minimize the risks associated with immunosuppressive medications, the first attempts in human recipients will likely be performed in conjunction with a FT. If first-in-human attempts at combined FT-WET prove successful and the biologic eye survives, this opens the door for further advancement in the field of vision restoration by means of a viable surgical option. This analysis integrates recent innovations in WET research with the existing discourse on the ethics of surgical innovation and offers preliminary guidance to VCA programs considering undertaking WET in human recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.